Slide 1: Announcement of Q3 2010 Results
Announcement of Q3 2010 Results Analyst / Investor Conference Call October 6, 2010 3:00 p.m. CEST Uwe Röhrhoff, CEO Jürgen Wiecha, CFO
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Agenda
Agenda Key Facts Q3 2010 and Guidance FY 2010 Uwe Röhrhoff, CEO Financial Overview Q3 2010 Jürgen Wiecha, CFO Appendix 3
Slide 4: Q3 2010 Financial Key Facts
Q3 2010 Financial Key Facts Strong increase in like-for-like revenues of 9.5% (+5.8% at constant exchange rates) Solid growth in the pharma business Rising capacity utilization in the Cosmetics business Market recovery in the Life Science Research segment Markedly increased results Adjus
Slide 5: Q3 2010 Operational Key Facts
Q3 2010 Operational Key Facts Tubular Glass Growth in RTF® syringes Bulk syringe business on the decline North America and China with growth in vials and ampules Plastic Systems Pen systems with strong performance Inhalation devices also driving growth Moulded Glass Rising capacity
Slide 6: Confirmation of FY 2010 Guidance
Confirm ation of FY 2010 Guidance 20091 Guidance 2010 Confirmed Guidance (as of Feb 10, 2010) 2010 (as of July 14, 2010) Net Revenues EUR 970.8m +2% to 4% as reported2 +5% to 6% as reported3 +2% to 4% at const. FX +3% to 4% at const. FX Adj. EBITDA 19.2% Mid 19% 19.5% to 20.0% margin Capex EUR 86.4m
Slide 7: Growth opportunities
Growth opportunities Pharmerging Markets: Doubling of revenues within next 3 years Generics companies: Exploitation of volume opportunities RTF market: Further increase of market share Diabetes market: Development and strenghtening of market position Acquisition strategy: Execution of (bol
Slide 8: Agenda
Agenda Key Facts Q3 2010 and Guidance FY 2010 Uwe Röhrhoff, CEO Financial Overview Q3 2010 Jürgen Wiecha, CFO Appendix 8
Slide 9: Q3 2010 P&L overview
Q3 2010 P&L overview Q3 2010 Q3 2009 EUR m EUR m in % Total revenues ex TPS 259.4 236.9 +9.5 Adjusted EBITDA1 53.3 42.0 +26.9 EBITA 32.1 22.4 +43.3 Amortization of FV adjustments 5.8 9.5 -39.0 Profit before interest and taxes (EBIT) 26.3 12.9 >100 Financial result -8.9 -9.9 -10.1 Profit before taxes
Slide 10: Q3 2010 Revenues by division
Q3 2010 Revenues by division EUR m Reported growth [%] FXN1 [%] Total revenues 259.4 +6.9 +3.4 Total revenues ex TPS 259.4 +9.5 +5.8 Tubular Glass 77.3 +4.3 -0.7 Plastic Systems 75.3 +0.7 -0.9 Plastic Systems ex TPS 75.3 +9.0 +7.1 Moulded Glass 85.2 +13.9 +11.5 Life Science Research 25.8 +18.3 +8.0
Slide 11: Q3 2010 Adjusted EBITDA & margin by division
Q3 2010 Adjusted EBITDA1 & margin by division Q3 2010 vs. Q3 2009 Q3 2010 Q3 2009 EUR m [Growth in %] [Margin in %] [Margin in %] Total Group 53.3 +26.9 20.5 17.3 Total Group ex TPS 53.3 +28.1 20.5 17.6 Tubular Glass 18.3 +4.0 23.7 23.8 Plastic Systems 17.5 +6.1 23.2 22.1 Plastic Systems ex TPS 17.5
Slide 12: Q3 2010 Key financial figures
Q3 2010 Key financial figures August 31, 2010 August 31, 2009 EUR m EUR m in % Equity 509.3 466.5 +9.2 Equity ratio in % 37.7 34.7 Net Working Capital 1 179.3 180.8 -0.8 in % of LTM revenues 17.8 17.7 Net Financial Debt 2 356.6 430.7 -17.2 Adjusted EBITDA leverage 1.7 2.3 n/a Q3 2010 Q3 2009 EUR m E
Slide 13: Financing structure
Financing structure Comparison of debt/cash positions in EUR m Net Financial Debt Q3 2009: 430.7m Q3 2010: 356.6m Interest rate (due date): Bond 126.0 7.9%; Fixed coupon 126.0 (2015) Hedged interest rate: 5.7% Long-term bank debt 209.6 until Sep 2010. As from Sep 2010 ca. 95% hedged at 188.3 1.8% un
Slide 14: Financial calendar
Financial calendar February 10, 2011 Annual Report 2010 April 7, 2011 Interim Report 1st Quarter 2011 April 14, 2011 Annual General Meeting July 13, 2011 Interim Report 2nd Quarter 2011 October 6, 2011 Interim Report 3rd Quarter 2011 14
Slide 15: Investor Relations contact details
Investor Relations contact details Phone +49 211 6181-257 Fax +49 211 6181-121 E-mail gerresheimer.ir@gerresheimer.com IR website www.gerresheimer.com/ir 15
Slide 16: Agenda
Agenda Key Facts Q3 2010 and Guidance FY 2010 Uwe Röhrhoff, CEO Financial Overview Q3 2010 Jürgen Wiecha, CFO Appendix 16
Slide 17: Q3 2010 Reconciliation from adjusted EBITDA to net income after minorities
Q3 2010 Reconciliation from adjusted EBITDA to net income after minorities EUR m Q3 2010 Q3 2009 Adjusted EBITDA 53.3 42.0 Restructuring expenses 0.1 0.3 One-off income/expense 0.3 0.6 EBITDA 52.9 41.1 Amortization of fair value adjustments 5.8 9.5 Depreciation and amortization 20.8 18.7 Profit from
Slide 18: Q1-Q3 2010 P&L overview
Q1-Q3 2010 P&L overview Q1-Q3 2010 Q1-Q3 2009 EUR m EUR m in % Total revenues ex TPS 753.0 714.9 +5.3 Adjusted EBITDA1 147.9 127.8 +15.7 EBITA 82.0 62.5 +31.2 Amortization of FV adjustments 18.6 28.6 -35.0 Profit before interest and taxes (EBIT) 63.4 33.9 +87.0 Financial result -26.9 -30.6 -12.1 Pro
Slide 19: Q1-Q3 2010 Revenues by division
Q1-Q3 2010 Revenues by division EUR m Reported growth [%] FXN1 [%] Total revenues 753.0 +1.2 +0.2 Total revenues ex TPS 753.0 +5.3 +4.4 Tubular Glass 234.3 +4.1 +3.0 Plastic Systems 221.6 -7.1 -8.4 Plastic Systems ex TPS 221.6 +6.0 +4.4 Moulded Glass 238.9 +6.2 +6.0 Life Science Research 69.8 +5.8 +
Slide 20: Q1-Q3 2010 Adjusted EBITDA & margin by division
Q1-Q3 2010 Adjusted EBITDA1 & margin by division Q1-Q3 2010 vs. Q1-Q3 ’09 Q1-Q3 2010 Q1-Q3 2009 EUR m [Growth in %] [Margin in %] [Margin in %] Total Group 147.9 +15.7 19.6 17.2 Total Group ex TPS 147.9 +15.5 19.6 17.9 Tubular Glass 56.3 +5.8 24.0 23.6 Plastic Systems 51.3 +8.0 23.1 19.9 Plastic Sys
Slide 21: Q1-Q3 2010 Reconciliation from adjusted EBITDA to net income after minorities
Q1-Q3 2010 Reconciliation from adjusted EBITDA to net income after minorities EUR m Q1-Q3 2010 Q1-Q3 2009 Adjusted EBITDA 147.9 127.8 Restructuring expenses 3.7 1.8 One-off income/expense 0.8 2.3 EBITDA 143.4 123.7 Amortization of fair value adjustments 18.6 28.6 Depreciation and amortization 61.4 5